Rodríguez-Pena M S, Guijarro L G, Prieto J C
Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.
Eur J Pharmacol. 1991 Nov 13;208(3):207-12. doi: 10.1016/0922-4106(91)90097-2.
Vasoactive intestinal peptide (VIP) receptors coupled to activation of adenylate cyclase have been previously identified in seminal vesicle membranes of rat. In the present study we demonstrate that the synthetic peptides [4-Cl-D-Phe6,Leu17]VIP and the growth hormone releasing factor (GRF) analog [Ac-Tyr1,D-Phe2]GRF1-29-NH2 inhibit in a competitive manner the specific 125I-VIP binding to the same membrane preparation. The order of potency of the two peptides compared to VIP was: VIP (IC50 = 1.3 +/- 0.5 nM) greater than [4-Cl-D-Phe6,Leu17]VIP(IC50 = 1600 +/- 45.0 nM) greater than [Ac-Tyr1,D-Phe2]GRF1-29-NH2(IC50 = 290.0 +/- 59.4 nM). Whereas VIP showed a stimulatory activity upon adenylate cyclase with a potency (ED50 = 7.0 +/- 0.7 nM) compatible with the affinity of the VIP binding sites previously described, the other two peptides tested showed no effect at that level. The behavior as antagonists of both [4-Cl-D-Phe6,Leu17]VIP and [Ac-Tyr1,D-Phe2]GRF1-29-NH2 was confirmed by: (a) the parallel shifts of the VIP dose-response curves for stimulation of adenylate cyclase activity in the presence of the antagonists; (b) the close agreement between the binding affinity and the inhibition of adenylate cyclase activity for the two peptides; and (c) the lack of effect of the two antagonists upon the adenylate cyclase activity stimulated by the beta-adrenoceptor agonist isoproterenol which indicates the specificity of the interaction.(ABSTRACT TRUNCATED AT 250 WORDS)
先前已在大鼠精囊膜中鉴定出与腺苷酸环化酶激活偶联的血管活性肠肽(VIP)受体。在本研究中,我们证明合成肽[4-氯-D-苯丙氨酸6,亮氨酸17]VIP和生长激素释放因子(GRF)类似物[乙酰基-酪氨酸1,D-苯丙氨酸2]GRF1-29-NH2以竞争性方式抑制特异性125I-VIP与相同膜制剂的结合。与VIP相比,这两种肽的效力顺序为:VIP(IC50 = 1.3±0.5 nM)大于[4-氯-D-苯丙氨酸6,亮氨酸17]VIP(IC50 = 1600±45.0 nM)大于[乙酰基-酪氨酸1,D-苯丙氨酸2]GRF1-29-NH2(IC50 = 290.0±59.4 nM)。虽然VIP对腺苷酸环化酶表现出刺激活性,其效力(ED50 = 7.0±0.7 nM)与先前描述的VIP结合位点的亲和力相符,但测试的其他两种肽在该水平上没有作用。[4-氯-D-苯丙氨酸6,亮氨酸17]VIP和[乙酰基-酪氨酸1,D-苯丙氨酸2]GRF1-29-NH2作为拮抗剂的行为通过以下方式得到证实:(a)在拮抗剂存在下,VIP剂量-反应曲线对腺苷酸环化酶活性刺激的平行移动;(b)两种肽的结合亲和力与腺苷酸环化酶活性抑制之间的密切一致性;以及(c)两种拮抗剂对β-肾上腺素能受体激动剂异丙肾上腺素刺激的腺苷酸环化酶活性没有影响,这表明相互作用的特异性。(摘要截断于250字)